Adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer riskShow others and affiliations
2016 (English)In: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 65, no 8, p. 1289-1295Article in journal (Refereed) Published
Abstract [en]
Objective: Adult obesity and inflammation have been associated with risk of colorectal cancer (CRC); however, less is known about how adolescent body mass index (BMI) and inflammation, as measured by erythrocyte sedimentation rate (ESR), relate to CRC risk. We sought to evaluate these associations in a cohort of 239 658 Swedish men who underwent compulsory military enlistment examinations in late adolescence (ages 16-20 years).
Design: At the time of the conscription assessment (1969-1976), height and weight were measured and ESR was assayed. By linkage to the national cancer registry, these conscripts were followed for CRC through 1 January 2010. Over an average of 35 years of follow-up, 885 cases of CRC occurred, including 501 colon cancers and 384 rectal cancers. Cox regression was used to estimate adjusted HRs and corresponding 95% CIs.
Results: Compared with normal weight (BMI 18.5 to <25 kg/m(2)) in late adolescence, upper overweight (BMI 27.5 to <30 kg/m(2)) was associated with a 2.08-fold higher risk of CRC (95% CI 1.40 to 3.07) and obesity (BMI 30+ kg/m(2)) was associated with a 2.38-fold higher risk of CRC (95% CI 1.51 to 3.76) (p-trend: <0.001). Male adolescents with ESR (15+ mm/h) had a 63% higher risk of CRC (HR 1.63; 95% CI 1.08 to 2.45) than those with low ESR (<10 mm/h) (p-trend: 0.006). Associations did not significantly differ by anatomic site.
Conclusions: Late-adolescent BMI and inflammation, as measured by ESR, may be independently associated with future CRC risk. Further research is needed to better understand how early-life exposures relate to CRC.
Place, publisher, year, edition, pages
London, United Kingdom: BMJ Publishing Group , 2016. Vol. 65, no 8, p. 1289-1295
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-44822DOI: 10.1136/gutjnl-2014-309007ISI: 000379756700009PubMedID: 25986947Scopus ID: 2-s2.0-84980649704OAI: oai:DiVA.org:oru-44822DiVA, id: diva2:816314
Note
Funding Agencies:
National Cancer Institute T32 CA 009001
Harvard School of Public Health
Örebro University Strategic Funding
UK Economic and Social Research Council (ESRC) RES-596-28-0001 ES/JO19119/1
2015-06-032015-06-032025-02-11Bibliographically approved